18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone.

about

18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone.

Item

http://www.wikidata.org/entity/Q41721716

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone.

@en

type

Item

label

18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone.

@en

prefLabel

18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone.

@en

P1476

18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone.

@en

P2093

Behrang Amini

http://www.w3.org/2001/XMLSchema#string

Colleen M Costelloe

http://www.w3.org/2001/XMLSchema#string

Hubert H Chuang

http://www.w3.org/2001/XMLSchema#string

John E Madewell

http://www.w3.org/2001/XMLSchema#string

Najat C Daw

http://www.w3.org/2001/XMLSchema#string

Tamara Miner Haygood

http://www.w3.org/2001/XMLSchema#string

Usama Salem

http://www.w3.org/2001/XMLSchema#string

Wei Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Intraclass correlations: uses in assessing rater reliability

Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data.

FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.

Overview of sarcomas in the adolescent and young adult population.

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.

Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future.

The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.

18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.

Diagnostic accuracy of ¹⁸F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis.

P304

2892-2898

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.20077

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28928879

http://www.w3.org/2001/XMLSchema#string

P932

5604439

http://www.w3.org/2001/XMLSchema#string